Candida infections in COVID-19 patients: A review of prevalence, risk factors, and mortality

IF 1.4 4区医学 Q4 IMMUNOLOGY

Indian Journal of Medical Microbiology Pub Date : 2025-03-27 DOI:10.1016/j.ijmmb.2025.100831

Eduardo Franco Tulio , Fabíola Lucini , Allan Carminatti de Lima , Natalia Daiane Garoni Martins do Carmo , Marcelo dos Santos Barbosa , Gleyce Hellen de Almeida de Souza , Luana Rossato

{"title":"Candida infections in COVID-19 patients: A review of prevalence, risk factors, and mortality","authors":"Eduardo Franco Tulio , Fabíola Lucini , Allan Carminatti de Lima , Natalia Daiane Garoni Martins do Carmo , Marcelo dos Santos Barbosa , Gleyce Hellen de Almeida de Souza , Luana Rossato","doi":"10.1016/j.ijmmb.2025.100831","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div><em>Candida</em> spp. infections have increasingly been reported among COVID-19 patients, yet the epidemiological factors, diagnostic methods, and outcomes associated with these infections remain poorly understood. These infections, particularly in ICU settings, present significant challenges due to high mortality rates and rising antifungal resistance. This study aimed to investigate the occurrence, risk factors, treatment, and outcomes of <em>Candida albicans</em> and non-<em>albicans Candida</em> in COVID-19 patients, providing clinical and epidemiological insights.</div></div><div><h3>Methods</h3><div>A review following PRISMA guidelines was conducted. Searches were performed in PubMed, Embase, and BVS databases, covering articles published from January 2020 to May 2024. Inclusion criteria included case reports or case series providing detailed information on <em>Candida</em> spp. in COVID-19 patients. Data extraction focused on patient demographics, underlying diseases, antifungal and antibiotic therapies, antifungal susceptibility, resistance profiles, and outcomes. Statistical analyses were conducted using SPSS software.</div></div><div><h3>Results</h3><div>The review included 67 studies, totaling 223 COVID-19 patients. Male patients were predominant. Common comorbidities included hypertension, cancer, and dyslipidemia. Echinocandins were the primary antifungal treatment. Non-<em>albicans Candida</em> exhibited a higher resistance rate (47.10 %) compared to <em>C. albicans</em> (2.35 %). Overall mortality rates were high, at 60.50 % for <em>C. albicans</em> and 62.30 % for non-<em>albicans</em>. Significant risk factors for mortality included age, central venous catheter use, ICU admission, and corticosteroid therapy.</div></div><div><h3>Conclusions</h3><div>The study identified critical risk factors and clinical characteristics in COVID-19 patients with <em>Candida</em> infections. The high incidence of antifungal resistance among non-<em>albicans</em> and high mortality rates highlight the need for vigilant monitoring and targeted antifungal strategies to improve outcomes.</div></div>","PeriodicalId":13284,"journal":{"name":"Indian Journal of Medical Microbiology","volume":"55 ","pages":"Article 100831"},"PeriodicalIF":1.4000,"publicationDate":"2025-03-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Medical Microbiology","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0255085725000441","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"IMMUNOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Candida spp. infections have increasingly been reported among COVID-19 patients, yet the epidemiological factors, diagnostic methods, and outcomes associated with these infections remain poorly understood. These infections, particularly in ICU settings, present significant challenges due to high mortality rates and rising antifungal resistance. This study aimed to investigate the occurrence, risk factors, treatment, and outcomes of Candida albicans and non-albicans Candida in COVID-19 patients, providing clinical and epidemiological insights.

Methods

A review following PRISMA guidelines was conducted. Searches were performed in PubMed, Embase, and BVS databases, covering articles published from January 2020 to May 2024. Inclusion criteria included case reports or case series providing detailed information on Candida spp. in COVID-19 patients. Data extraction focused on patient demographics, underlying diseases, antifungal and antibiotic therapies, antifungal susceptibility, resistance profiles, and outcomes. Statistical analyses were conducted using SPSS software.

Results

The review included 67 studies, totaling 223 COVID-19 patients. Male patients were predominant. Common comorbidities included hypertension, cancer, and dyslipidemia. Echinocandins were the primary antifungal treatment. Non-albicans Candida exhibited a higher resistance rate (47.10 %) compared to C. albicans (2.35 %). Overall mortality rates were high, at 60.50 % for C. albicans and 62.30 % for non-albicans. Significant risk factors for mortality included age, central venous catheter use, ICU admission, and corticosteroid therapy.

Conclusions

The study identified critical risk factors and clinical characteristics in COVID-19 patients with Candida infections. The high incidence of antifungal resistance among non-albicans and high mortality rates highlight the need for vigilant monitoring and targeted antifungal strategies to improve outcomes.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Indian Journal of Medical Microbiology IMMUNOLOGY-

CiteScore

2.20

自引率

0.00%

发文量

154

审稿时长

73 days

期刊介绍： Manuscripts of high standard in the form of original research, multicentric studies, meta analysis, are accepted. Current reports can be submitted as brief communications. Case reports must include review of current literature, clinical details, outcome and follow up. Letters to the editor must be a comment on or pertain to a manuscript already published in the IJMM or in relation to preliminary communication of a larger study. Review articles, Special Articles or Guest Editorials are accepted on invitation.